The UK company reveals the results from a partner-led survey to discover the rates of vaccination for adults, why levels are lower than expected, and what can be done to improve this.
Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second ph
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to metho